Lara Sullivan
2021
In 2021, Lara Sullivan earned a total compensation of $17.3M as Chief Executive Officer at Pyxis Oncology, a 3,011% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $341,825 |
|---|---|
| Option Awards | $16,361,511 |
| Salary | $565,000 |
| Total | $17,268,336 |
Sullivan received $16.4M in option awards, accounting for 95% of the total pay in 2021.
Sullivan also received $341.8K in non-equity incentive plan and $565K in salary.
Rankings
In 2021, Lara Sullivan's compensation ranked 415th out of 12,415 executives tracked by ExecPay. In other words, Sullivan earned more than 96.7% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 415 out of 12,415 | 97th |
Division Manufacturing | 130 out of 5,505 | 98th |
Major group Chemicals And Allied Products | 39 out of 2,375 | 98th |
Industry group Drugs | 34 out of 2,096 | 98th |
Industry Pharmaceutical Preparations | 20 out of 1,546 | 99th |
Source: SEC filing on April 28, 2022.
Sullivan's colleagues
We found two more compensation records of executives who worked with Lara Sullivan at Pyxis Oncology in 2021.